SNRI vs. TCA Antidepressants

May 8, 2026

Upload by Patrick

This document provides a comparative overview of Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Tricyclic Antidepressants (TCAs), focusing on their indications, patient education points, and key administration warnings. It details Duloxetine (DUAL-OXETINE) as an SNRI, highlighting its dual purpose for depression and neuropathic pain, particularly in diabetic and fibromyalgia patients, emphasizing the need for patient education regarding its pain-management benefits. For TCAs, Amitriptyline and Imipramine are discussed. Amitriptyline is associated with a risk of orthostatic hypotension, advising slow positional changes. The mnemonic "Amy trips on things" is offered to remember this. Imipramine is also linked to orthostatic hypotension and urinary retention, with the mnemonic "Inhibit my PEEING" to help recall the latter. A critical safety warning is prominently displayed: never take TCAs, SNRIs, or SSRIs with Monoamine Oxidase Inhibitors (MAOIs), and a mandatory two-week "wash-out" period is required when switching between these medication classes to prevent dangerous serotonin syndrome. The document underscores the importance of patient understanding of medication mechanisms and potential side effects, particularly for conditions like fibromyalgia where the antidepressant may primarily address pain. General notes on these antidepressant classes are also included, stressing careful patient management and adherence to safety protocols.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

May 8, 2026

Upload by Patrick